MedTrace Logo

A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers

NCT01314898 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2011-07-06

No results posted yet for this study

Summary

24-hr urinary sodium/potassium ratio will be a sensitive biomarker of antimineralocorticoid activity. The dose-response relationship of the antimineralocorticoid activity of PF-03882845 can be established following single oral doses.

Conditions

  • Healthy Volunteers

Interventions

DRUG

3 mg PF-03882845

3 mg PF-03882845, single oral dose

DRUG

10 mg PF-03882845

10 mg PF-03882845, single oral dose

DRUG

30 mg PF-03882845

30 mg PF-03882845, single oral dose

DRUG

100 mg PF-03882845

100 mg PF-03882845, single oral dose

DRUG

Spironolactone

100 mg spironolactone, single oral dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01314898 on ClinicalTrials.gov